Galera Therapeutics, Inc. (GRTX)
OTCMKTS · Delayed Price · Currency is USD
0.0222
0.00 (0.00%)
May 2, 2025, 10:22 AM EDT

Galera Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Net Income
-18.96-59.08-62.22-80.53-74.22
Upgrade
Depreciation & Amortization
0.020.260.110.780.37
Upgrade
Loss (Gain) From Sale of Assets
0.05-0.07---
Upgrade
Asset Writedown & Restructuring Costs
6.98----
Upgrade
Stock-Based Compensation
2.555.567.167.235.54
Upgrade
Other Operating Activities
-0.6611.4111.57.194.86
Upgrade
Change in Accounts Payable
-1.42-2.21-1.46-0.11.2
Upgrade
Change in Other Net Operating Assets
-0.71-0.721.48-2.532.71
Upgrade
Operating Cash Flow
-12.15-44.85-43.43-67.96-59.54
Upgrade
Capital Expenditures
--0.06-0.03-0.28-0.46
Upgrade
Sale of Property, Plant & Equipment
0----
Upgrade
Cash Acquisitions
-0.05----
Upgrade
Investment in Securities
-27.3524.025.5237
Upgrade
Investing Cash Flow
-0.0527.2923.995.2436.55
Upgrade
Long-Term Debt Issued
---57.520
Upgrade
Net Debt Issued (Repaid)
---57.520
Upgrade
Issuance of Common Stock
2.2231.53.899.210.51
Upgrade
Financing Cash Flow
2.2231.53.8966.7120.51
Upgrade
Net Cash Flow
-9.9713.94-15.543.99-2.48
Upgrade
Free Cash Flow
-12.15-44.91-43.45-68.24-59.99
Upgrade
Free Cash Flow Per Share
-0.22-1.01-1.60-2.65-2.41
Upgrade
Levered Free Cash Flow
-7.78-35.66-32.1-44.7-37.24
Upgrade
Unlevered Free Cash Flow
-7.78-28.53-24.87-40.2-34.19
Upgrade
Change in Net Working Capital
1.54.950.112.08-4.46
Upgrade
Updated Dec 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.